Personal Injury
Testing the Market Impact of Drug Price Program on Stelara Biosimilars
The Biden administration’s implementation of the Medicare drug pricing program could alter drugmaker strategy on biosimilars, highlighted by the recent approval of...
Personal Injury
New FDA Rule Mandates Disclosure of Prescription Drug Side-Effects in Advertising
Prescription drug advertisements presented in media such as television and radio must disclose the product’s major side-effects and contraindications, the FDA said...
Personal Injury
Tobacco Industry Pushes Back Against FDA’s Proposed Ban on Flavored Cigars
The FDA has not yet finalized its plan to remove flavored cigars from store shelves, but it is facing strong...
Personal Injury
Ohio Voters Approved Abortion Ban, But Courts Will Determine its Impact
Ohio voters approved a measure last week to enshrine abortion rights in the state constitution, but supporters and opponents of Issue 1...
Personal Injury
Debate on FDA Preemption Continues with Michigan Pharma Shield Law
The Michigan Legislature’s vote to repeal a one-of-a-kind law shielding drugmakers from liability lawsuits will force courts to balance consumer interests with...
Personal Injury
FDA Hearing Focuses on Unproven $900,000 Drug for Lethal Cancer
The cancer drug Folotyn, one of the most expensive in the US, received a short-cut approval from US regulators to treat a...
Personal Injury
Federal Judge Halts Idaho Ban on Abortion ‘Trafficking’
Idaho is unable to enforce a law that prohibits reproductive rights advocates from assisting minors with obtaining abortions without parental consent, as...
Personal Injury
Amgen’s Wezlana Faces Legal Obstacles in Drug Pricing Battle
The FDA’s approval of Wezlana as an interchangeable biosimilar to inflammatory disease drug Stelara underscores the legal obstacles the pharmaceutical industry faces...